Table 3.

Baseline characteristics of the patients with visceral leishmaniasis, who received Glucantime for 1 week (group I), 2 weeks (group II), and 3 weeks (group III) after defervescence in the second phase of the study

	Group I (N = 25)	Group II (N = 25)	Group III (N = 25)
Characteristic
Age (month)	28.16	27.44	29.32
Underweight (%)	40	36	44
Short stature (%)	68	64	68
Nomadic lifestyle (%)	64	68	68
Signs and symptoms
Splenomegaly (%)	84	100	96
Hepatomegaly (%)	56	52	48
Jaundice (%)	12	8	12
Ascites (%)	12	8	12
Petechia/purpura (%)	12	12	12
Fever (%)	96	100	92
Malnutrition (%)	72	68	76
Edema (%)	16	12	8
Diarrhea (%)	12	12	16
Lymphadenopathy (%)	0	0	0